Showing results (1-10 of 261) with videos related to
Sort By:
Pageof 27
Cold Spring Harbor Perspectives in Biology|February 26, 2010
Mutant p53 gain-of-function in cancerMoshe Oren, Varda RotterOncotarget|March 5, 2016
Cancer therapeutic approach based on conformational stabilization of mutant p53 protein by small peptidesPerry Tal, Shay Eizenberger, Elad Cohen, et al.Oncotarget|June 14, 2019
Correction: Cancer therapeutic approach based on conformational stabilization of mutant p53 protein by small peptidesPerry Tal, Shay Eizenberger, Elad Cohen, et al.Genes & Cancer|July 23, 2011
Mutations in the p53 Tumor Suppressor Gene: Important Milestones at the Various Steps of TumorigenesisNoa Rivlin, Ran Brosh, Moshe Oren, et al.Aging|February 17, 2010
Coupling transcriptional and post-transcriptional miRNA regulation in the control of cell fateReut Shalgi, Ran Brosh, Moshe Oren, et al.Plos One|December 31, 2009
Discovery of novel proteasome inhibitors using a high-content cell-based screening systemIrena Lavelin, Avital Beer, Zvi Kam, et al.Haematologica|February 24, 2022
Pseudo-mutant P53 is a unique phenotype of <i>DNMT3A</i>-mutated pre-leukemiaAmos Tuval, Yardena Brilon, Hadas Azogy, et al.Cancer Research|November 19, 2004
Transactivation of the EGR1 gene contributes to mutant p53 gain of functionLilach Weisz, Amir Zalcenstein, Perry Stambolsky, et al.International Journal of Cancer|December 24, 2016
Immune deficiency augments the prevalence of p53 loss of heterozygosity in spontaneous tumors but not bi-directional loss of heterozygosity in bone marrow progenitorsYoav Shetzer, Yael Napchan, Tom Kaufman, et al.Cell Death and Differentiation|May 14, 2024
Mutant p53 reactivation restricts the protumorigenic consequences of wild type p53 loss of heterozygosity in Li-Fraumeni syndrome patient-derived fibroblastsHimanshi Agarwal, Perry Tal, Naomi Goldfinger, et al.Pageof 27